Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

In Vitro and In Vivo Characterization of MCT1 Inhibitor AZD3965 Confirms Preclinical Safety Compatible with Breast Cancer Treatment

2 Feb 2021

Abstract excerpt

To survive and proliferate in solid tumors, cancer cells adapt and evolve rapidly in microenvironments where oxygen and substrate bioavailability fluctuates over time and space. This creates metabolic heterogeneity. Cancer cells can further cooperate metabolically, for example by swapping glycolytic end-product lactate for blood-borne glucose. This type of cooperation can be targeted therapeutically, since...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adipose Tissue and Metabolism
Share to Cancer, Hypoxia, and Metabolism
Share to Mitochondrial Function and Pathology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33540599
DOI: 10.3390/cancers13030569

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

In Vitro and In Vivo Characterization of MCT1 Inhibitor AZD3965 Confirms Preclinical Safety Compatible with Breast Cancer TreatmentPMID 33540599Read ↗

Preclinical Efficacy of the Novel Monocarboxylate Transporter 1 Inhibitor BAY-8002 and Associated Markers of ResistanceSemantic proximity Read ↗

Functional screening identifies MCT4 as a key regulator of breast cancer cell metabolism and survivalSemantic proximity Read ↗

Therapy-induced DNA methylation inactivates MCT1 and renders tumor cells vulnerable to MCT4 inhibition.Semantic proximity Read ↗

Role of Human Monocarboxylate Transporter 1 (hMCT1) and 4 (hMCT4) in Tumor Cells and the Tumor MicroenvironmentSemantic proximity Read ↗

Lactate Metabolism Regulates Tumour Growth and Progression in GlioblastomaSemantic proximity Read ↗

LC-mHTT-AN2 oversees lactate transport, hypoxia, and glucose homeostasis through dual regulation of MCT-1/4 in the tumor microenvironmentSemantic proximity Read ↗

The monocarboxylate transporter family--role and regulation.Semantic proximity Read ↗

CRISPR screens reveal MCT1-driven metabolic escape from SMAD3 inhibition as a therapeutic vulnerabilitySemantic proximity Read ↗

Lactate-Driven Heterogeneity of Immune Checkpoint Expression in Breast and Lung Cancer Cell LinesSemantic proximity Read ↗

Targeting LKB1/STK11-mutant cancer: distinct metabolism, microenvironment, and therapeutic resistance.Semantic proximity Read ↗

Evidence for a stromal-epithelial “lactate shuttle” in human tumorsSemantic proximity Read ↗

Inhibition of the succinyl dehydrogenase complex in acute myeloid leukemia leads to a lactate-fuelled respiratory metabolic vulnerability.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.